| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Profit before tax | -1.3 | -0.3 |
| Net income | -1.3 | -0.3 |
| EPS (diluted, $ a share) | $-0.00 | $-0.00 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, OTC: BIXT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Bioxytran, Inc: key numbers
- Share price
- $0.0220Close, Nov 20
- Market cap
- $2.52M
- Shares outstanding
- 114.7MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Bioxytran, Inc
All →Bioxytran Product Launch
Bioxytran, Inc. announced the commercial launch of its first two nutraceutical products, A-SUQAR for metabolic support and V-LO for immune support. The launch marks the clinical-stage biotech's expansion into the consumer wellness market, utilizing its carbohydrate-chemistry expertise. Both products are available immediately through the company's online storefront.
“For years, our team has worked on complex therapeutics for critical care and infectious diseases. Today we are bringing that same science directly to people’s doorsteps. Our entry into nutraceuticals is driven by a simple principle: apply rigorous scientific standards to everyday health. We have held these products to the same diligence we apply to our drug programs, so consumers get a high-quality, science-backed supplement they can trust.”
David Platt, Ph.D., Chief Executive Officer of Bioxytran
Bioxytran Regulatory Approval
Bioxytran secured a government-issued Free Sale Certificate for its A-SUQAR chewable nutraceutical, a key regulatory milestone for market entry in the UAE and Gulf Cooperation Council region. The certification confirms the product is lawfully manufactured and sold as a health supplement, allowing the company to proceed with product registration in markets with high diabetes prevalence.